Seema Basi, M.D., M.S.C.I., F.A.S.N.
High School: West Windsor Plainsboro South, Princeton Junction, NJ - National Merit Finalist
Undergraduate College: Northwestern University, Evanston, IL. Major in Molecular Biology
Medical School: Northwestern University Medical School, Chicago, IL
Internal Medicine Residency: Baylor College of Medicine Medical Center, Houston, TX
Nephrology Fellowship: Vanderbilt University Medical Center, Nashville, TN
Masters of Science in Clinical Investigation: Vanderbilt University, Nashville, TN
Current Academic Position
Clinical Associate Professor, Rutgers-Robert Wood Johnson Medical School, Piscataway, NJ
Medical Director, DaVita Princeton Junction Dialysis
Medical Director, DaVita Monroe Dialysis
2017 - Designated as a Certified Hypertension Specialist by the American Hypertension Specialist Certification Program
2007 - Designated as a Specialist in Clinical Hypertension by the American Society of Hypertension
Board Certified in Internal Medicine and Nephrology
Honors and Awards
- Fellow of the American Society of Nephrology
- 2017 Patient-Centered Outcomes Research Institute (PCORI) Tier A Pipeline to Proposal Award
- 2017 Davita Core Value Award
- 2014 Volunteer Faculty Award - Rutgers-RWJMS
- 2006 & 2007 Excellence in Teaching Award, St.Peters University Hospital/Drexel University College of Medicine
- 2004 - NIH funded Clinical Research Scholar
- 2004 - NKF Postdoctoral Research fellowship Grant
- 2003 - Honorable Mention for Outstanding contribution to clinical research – Amgen Young Investigators Forum
- 2002 - Award for Excellence in Ambulatory Medicine, Baylor College of Medicine
- Elected to Phi Beta Kappa as an undergraduate (junior year)
- 7 year Honors Program for combined BA/MD degree at Northwestern University
2017-2018 Improving the Provision of Mental Health Care for Patients with End Stage Renal Disease and their Caregivers
2009-2010 Collaborative Study Group Trial of Pyridorin in Overt Diabetic Nephropathy (Phase IIb)
2007-2010 Altitude Study: Examining Effect of Renin-inhibitor Aliskiren on Cardiovascular and Renal Outcomes (Phase IV)
2005-2008 The Effect of Sulodexide in Patients with Type 2 Diabetes and Microalbuminuria or Overt Diabetic Nephropathy (Collaborative Study Group) (Phase III)
Basi S., Fesler P., Mimran A., Lewis JB. Microalbuminuria in Type 2 Diabetes and Hypertension: a Marker, Treatment Target, or Innocent Bystander? Diabetes Care. 2008 Feb;31 Suppl 2:S149-201.
Basi S., Lewis JB. Microalbuminuria as a Target to Improve Cardiovascular and Renal Outcomes in Diabetic Patients. Current Diabetes Reports. 2007 Dec;7(6):439-42.
Basi S., Lewis JB. Microalbuminuria as a Target to Improve Cardiovascular and Renal Outcomes. AM J Kidney Dis. 2006 Jun;47(6):927-46.
Basi S., Pupim LB., Simmons EM., Sezer MT., Shyr Y., Freedman S., Chertow GM., Mehta RL., Paganini E., Himmelfarb J., Ikizler TA. Insulin Resistance in Critically ill Patients with Acute Renal Failure. Am J Physiol Renal Physiol. 2005 Aug;289(2):F259-64. Epub 2005 Apr 19.
Basi S., Schulman G., Fogo AB Multiple Complications in Multiple Myeloma. Am J Kidney Dis. 2005 Mar;45(3):619-23.